Why is minoxidil described as a prodrug?

Because the molecule applied to the scalp is inactive. Sulfotransferase enzymes in the outer root sheath of the follicle convert minoxidil to minoxidil sulfate, which is the form that acts on the follicle. The amount of that enzyme varies between people, and a 2020 study by Ramos and colleagues reported that enzyme activity measured in plucked follicles predicted who responded to topical minoxidil.

Why is tretinoin combined with minoxidil in compounded solutions?

A 2019 study by Sharma, Goren and colleagues reported that five days of topical tretinoin raised follicular sulfotransferase expression and converted 43% of predicted minoxidil non-responders into responders. That enzyme-induction finding is the rationale for the minoxidil and tretinoin solution. The pairing itself was reported by Bazzano and colleagues in 1986, before the mechanism was described.

Is a compounded minoxidil solution the same as the approved over-the-counter product?

No. Topical minoxidil at 2% and 5% is FDA-approved as an over-the-counter product. A compounded solution that adds tretinoin, finasteride, azelaic acid or ketoconazole is prepared under section 503A to an individual prescription, carries a beyond-use date rather than a shelf life, and has not been evaluated by the FDA. Where it contains finasteride, the FDA alert on compounded topical finasteride applies.

Is there a trial of the minoxidil, azelaic acid, finasteride and ketoconazole solution?

No trial of that four-ingredient combination has been published. Two of its ingredients, finasteride and minoxidil, have randomised trials of a two-ingredient solution behind them, pooled in a 2025 meta-analysis. Ketoconazole and azelaic acid have shampoo studies and in vitro work respectively. The component studies do not amount to evidence for the combination.

Does ExaVeyra say which minoxidil solution a practice should use?

No. ExaVeyra is a supplier and takes no part in prescribing decisions. The compounded hair and scalp formulations page lists what the 503A pharmacy partner can prepare and how each solution is dated. Which solution, if any, suits a given patient rests with the prescriber.

Esta referencia está disponible actualmente en inglés. La versión en español está en preparación.

Evidencia sobre cabello y cuero cabelludo

Minoxidil, Minoxidil Sulfate, and Follicular Sulfotransferase

Revisado por el equipo editorial de ExaVeyra Sciences · Actualizado el 15 de septiembre de 2026

ExaVeyra Sciences es un proveedor B2B con sede en Miami que suministra exosomas para uso en investigación a clínicas con licencia, y remite a los prescriptores con licencia a una farmacia de preparados compuestos 503A que prepara formulaciones según prescripciones individuales.

Qué cubre esta página, quién puede comprar a ExaVeyra, y qué se suministra
Pregunta	Respuesta
Qué es esto	Why minoxidil is a prodrug, what follicular sulfotransferase activity predicts, how tretinoin enters the picture, and what the combination solutions contain.
Quién puede comprar	Clínicas y profesionales con licencia, después de que ExaVeyra verifique una licencia profesional activa y el NPI y, para material de exosomas, un reconocimiento firmado de uso en investigación.
Qué se envía o se proporciona	Formatos de exosomas para uso en investigación y dispositivos de PRP se envían desde ExaVeyra a través de una cuenta verificada; las formulaciones compuestas las prepara y dispensa nuestra farmacia asociada 503A según una prescripción individual y no se envían desde ExaVeyra. Se emite un certificado de análisis para cada lote y se entrega a solicitud.

Minoxidil arrives at the hair follicle as an inactive molecule. Sulfotransferase enzymes in the outer root sheath convert it to minoxidil sulfate, the form that opens potassium channels and acts on the follicle, and the amount of that enzyme a given scalp carries varies widely between people. Topical minoxidil at 2% and 5% is FDA-approved as an over-the-counter product; the compounded solutions that pair it with tretinoin, or with finasteride, azelaic acid and ketoconazole, are prescription products prepared under section 503A. This page sets out the prodrug chemistry, the response literature built on it, and the rationale behind each combination.

It is an evidence reference. The compounded hair and scalp formulations page on this site lists the solutions the 503A pharmacy partner can prepare and how each is dated, and it deliberately says nothing about what any of them does to hair. Neither does this page.

A prodrug, and the enzyme that activates it

Minoxidil was developed as an oral antihypertensive, and hair growth was recorded as an adverse effect before it was studied as a topical agent. The active species is minoxidil sulfate, produced from minoxidil by sulfotransferase enzymes, and in the scalp that conversion happens in the follicle itself. A topical solution therefore depends on two things: the concentration applied and the enzymatic capacity of the follicles it reaches.

The second of those was the neglected variable for decades. The non-response rate to topical minoxidil was discussed in the literature in the context of adherence, formulation and disease severity, and a good part of it turned out to be enzymatic. Ramos and colleagues reported in Dermatologic Therapy in 2020 that sulfotransferase activity measured in plucked hair follicles predicted which women with pattern hair loss responded to topical minoxidil, and a 2021 study by the same group in the Journal of the European Academy of Dermatology and Venereology reported that genetic variants of the SULT1A1 enzyme predicted response to oral minoxidil.

Tretinoin as an enzyme inducer

Tretinoin enters the minoxidil story as an inducer of the enzyme rather than as a hair molecule in its own right. Sharma, Goren and colleagues reported in Dermatologic Therapy in 2019 that five days of topical tretinoin raised follicular sulfotransferase expression, and that 43% of subjects predicted by the enzyme assay to be minoxidil non-responders were converted to responders after that course. That study is the mechanistic basis for the minoxidil and tretinoin solutions in compounded formularies.

The pairing is older than the mechanism. Bazzano and colleagues reported on topical tretinoin with minoxidil in the Journal of the American Academy of Dermatology in 1986, and the combination sat in dermatology practice for three decades on an empirical footing before the sulfotransferase work explained why it might matter. A reader comparing the two papers is reading the same observation from opposite ends.

What the approved product is, and what a compounded solution is

Topical minoxidil at 2% and 5% is FDA-approved as an over-the-counter product, and the 2017 meta-analysis by Adil and Godwin in the Journal of the American Academy of Dermatology reported that it outperformed placebo on hair count across pooled randomised trials. That is the approved product and its evidence.

A compounded solution that adds tretinoin, or that adds finasteride, azelaic acid and ketoconazole to 5% minoxidil, is a different product. It is prepared under section 503A of the Federal Food, Drug, and Cosmetic Act to an individual prescription, it is dated with a beyond-use date rather than a shelf life, and it has not been evaluated by the FDA for safety, effectiveness or quality. Where a compounded solution contains finasteride, the FDA alert on compounded topical finasteride, discussed on the finasteride page of this cluster, applies to it.

The combinations, and the rationale behind each ingredient

Ingredient	Rationale in the literature	Evidence for the combination itself
Tretinoin 0.025%	Induces follicular sulfotransferase; converted predicted non-responders in a 2019 study	A 1986 report of the pairing; the 2019 enzyme study
Finasteride 0.1%	Type II 5-alpha-reductase inhibition in the follicle	A 2025 meta-analysis of seven trials of a mixed solution; a 2022 phase III trial of a 0.25% spray on its own
Ketoconazole 2%	Studied as a shampoo in a 1998 report; proposed as an adjunct to finasteride in a 2004 hypothesis paper	None for the four-ingredient combination
Azelaic acid 12.5%	Reported to inhibit 5-alpha-reductase in human skin in a 1988 in vitro study	None for the four-ingredient combination

The table separates two things that marketing tends to merge. Each ingredient has a rationale in the literature, and for two of them the literature includes randomised trials of a two-ingredient solution. No trial of the four-ingredient combination has been published, and a page that presented the component studies as evidence for the combination would be making a claim the studies do not carry.

Ketoconazole and azelaic acid have their own evidence page in this cluster, which takes the shampoo studies and the in vitro work at their own level of detail.

What a formulary reader takes from this

Minoxidil is a prodrug; its active form is made in the follicle by sulfotransferase, and enzyme activity varies between people.
Follicular sulfotransferase activity has been reported to predict response to topical minoxidil, and SULT1A1 variants to predict response to oral minoxidil.
Tretinoin has been reported to induce the enzyme, which is the rationale for the minoxidil and tretinoin solution.
Approved topical minoxidil is an over-the-counter product; every combination solution is a compounded prescription product with a beyond-use date.
No trial of the four-ingredient solution exists; its ingredients are supported individually and at different levels.

Fuentes

FDA, Compounding and the FDA: Questions and Answers (consultado el 15 de septiembre de 2026)
FDA alerts health care providers, compounders and consumers of potential risks associated with compounded topical finasteride products (April 22, 2025) (consultado el 15 de septiembre de 2026)
DailyMed, finasteride tablet 1 mg, prescribing information (National Library of Medicine) (consultado el 15 de septiembre de 2026)

Literatura científica

Cada fuente indica qué tipo de estudio fue y, cuando el estudio incluyó personas, cuántas. El diseño del estudio determina qué puede establecer un resultado, de modo que se declara en lugar de dejarlo a la inferencia. Cada línea señala además qué aporta esa fuente en esta página.

Ramos PM, Sinclair RD, Kasprzak M, Miot HA Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil treatment in Brazilian female pattern hair loss patients. Dermatologic Therapy, 2020. doi:10.1111/dth.13195 PMID:31846181Clinical studySource 1 supports: The report that follicular sulfotransferase activity predicted response to topical minoxidil, cited for the enzymatic explanation of non-response.
Ramos PM, et al. Minoxidil sulfotransferase enzyme (SULT1A1) genetic variants predicts response to oral minoxidil treatment for female pattern hair loss. Journal of the European Academy of Dermatology and Venereology, 2021. doi:10.1111/jdv.16765 PMID:32567076Clinical studySource 2 supports: The genetic counterpart of the enzyme-activity finding, cited to show the same mechanism reported for the oral route.
Sharma A, Goren A, Dhurat R, et al. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatologic Therapy, 2019. doi:10.1111/dth.12915 PMID:30974011Clinical studySource 3 supports: The enzyme-induction study behind the minoxidil and tretinoin solution, cited for the 43% conversion of predicted non-responders.
Bazzano GS, Terezakis N, Galen W Topical tretinoin for hair growth promotion. Journal of the American Academy of Dermatology, 1986. doi:10.1016/s0190-9622(86)80024-x PMID:3771854Clinical studyLandmarkSource 4 supports: The original report of the tretinoin and minoxidil pairing, cited to show the combination predates the mechanism by three decades.
Adil A, Godwin M The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2017. doi:10.1016/j.jaad.2017.02.054 PMID:28396101Meta-analysisSource 5 supports: The pooled randomised evidence for approved topical minoxidil against placebo on hair count.
Frontiers in Medicine (Lausanne), 2025 Comparing minoxidil-finasteride mixed solution with minoxidil solution alone for male androgenetic alopecia: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Medicine, 2025. PMID:41127390Meta-analysis396 participantsSource 6 supports: The pooled evidence for the two-ingredient minoxidil and finasteride solution, cited in the combinations table.
Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology, 1998. doi:10.1159/000017954 PMID:9669136Clinical studySource 7 supports: The shampoo study that supplies the ketoconazole rationale in the combinations table.
Stamatiadis D, Bulteau-Portois MC, Mowszowicz I Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. British Journal of Dermatology, 1988. doi:10.1111/j.1365-2133.1988.tb03474.x PMID:3207614In vitroSource 8 supports: The in vitro 5-alpha-reductase finding that supplies the azelaic acid rationale in the combinations table.
Suchonwanit P, Thammarucha S, Leerunyakul K Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy, 2019. doi:10.2147/DDDT.S214907 PMID:31496654Narrative reviewSource 9 supports: The standard review of minoxidil pharmacology, cited for the prodrug chemistry and the sulfotransferase activation step.
Randolph M, Tosti A Oral minoxidil treatment for hair loss: a review of efficacy and safety. Journal of the American Academy of Dermatology, 2021. doi:10.1016/j.jaad.2020.06.1009 PMID:32622136Narrative reviewSource 10 supports: The review of the oral route, cited so the enzyme literature on oral minoxidil can be read in its context.
Dhurat R, Daruwalla S, Pai S, et al. SULT1A1 (minoxidil sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth. Journal of Cosmetic Dermatology, 2022. doi:10.1111/jocd.14299 PMID:34133836Randomised controlled trialSource 11 supports: A randomised trial of an enzyme-booster approach to topical minoxidil, cited as the controlled test of the induction rationale.
Jimenez-Cauhe J, Vano-Galvan S, Mehta N, et al. Hair follicle sulfotransferase activity and effectiveness of oral minoxidil in androgenetic alopecia. Journal of Cosmetic Dermatology, 2024. doi:10.1111/jocd.16473 PMID:39034734Clinical studySource 12 supports: The report relating follicular sulfotransferase activity to the oral route, cited to show the enzyme finding extends beyond topical use.
Gupta AK, Venkataraman M, Talukder M, Bamimore MA Relative efficacy of minoxidil and the 5-alpha reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis. JAMA Dermatology, 2022. doi:10.1001/jamadermatol.2021.5743 PMID:35107565Meta-analysisSource 13 supports: The network meta-analysis ranking minoxidil against the 5-alpha-reductase inhibitors in men, cited for the comparative picture.
Maas D, Spindler A, Zappi I, et al. Efficacy of topical tretinoin and topical minoxidil cotherapy in androgenetic alopecia: a review. Skin Appendage Disorders, 2026. doi:10.1159/000553018 PMID:42535115Narrative reviewSource 14 supports: The 2026 review of the tretinoin and minoxidil pairing, cited for its survey of the co-therapy literature from 1986 to the enzyme studies.

Solicitar acceso mayorista Consultar a nuestro equipo

Preguntas frecuentes

Why is minoxidil described as a prodrug?: Because the molecule applied to the scalp is inactive. Sulfotransferase enzymes in the outer root sheath of the follicle convert minoxidil to minoxidil sulfate, which is the form that acts on the follicle. The amount of that enzyme varies between people, and a 2020 study by Ramos and colleagues reported that enzyme activity measured in plucked follicles predicted who responded to topical minoxidil.
Why is tretinoin combined with minoxidil in compounded solutions?: A 2019 study by Sharma, Goren and colleagues reported that five days of topical tretinoin raised follicular sulfotransferase expression and converted 43% of predicted minoxidil non-responders into responders. That enzyme-induction finding is the rationale for the minoxidil and tretinoin solution. The pairing itself was reported by Bazzano and colleagues in 1986, before the mechanism was described.
Is a compounded minoxidil solution the same as the approved over-the-counter product?: No. Topical minoxidil at 2% and 5% is FDA-approved as an over-the-counter product. A compounded solution that adds tretinoin, finasteride, azelaic acid or ketoconazole is prepared under section 503A to an individual prescription, carries a beyond-use date rather than a shelf life, and has not been evaluated by the FDA. Where it contains finasteride, the FDA alert on compounded topical finasteride applies.
Is there a trial of the minoxidil, azelaic acid, finasteride and ketoconazole solution?: No trial of that four-ingredient combination has been published. Two of its ingredients, finasteride and minoxidil, have randomised trials of a two-ingredient solution behind them, pooled in a 2025 meta-analysis. Ketoconazole and azelaic acid have shampoo studies and in vitro work respectively. The component studies do not amount to evidence for the combination.
Does ExaVeyra say which minoxidil solution a practice should use?: No. ExaVeyra is a supplier and takes no part in prescribing decisions. The compounded hair and scalp formulations page lists what the 503A pharmacy partner can prepare and how each solution is dated. Which solution, if any, suits a given patient rests with the prescriber.

Lecturas relacionadas

Compounded hair and scalp formulations Finasteride: mechanism, approved label, and topical literature Hair and scalp protocol components in 2026 Reading the evidence behind a product claim

Estas afirmaciones no han sido evaluadas por la FDA. Los productos no están destinados a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. No existen productos de exosomas aprobados por la FDA. El material de exosomas distribuido por ExaVeyra Sciences se suministra únicamente para uso en investigación, para aplicaciones de investigación médica, de biología molecular y de bioquímica, y ExaVeyra Sciences no hace ninguna afirmación sobre administración, vía ni resultado. Los medicamentos compuestos son una clase de producto distinta: no son productos farmacéuticos terminados aprobados por la FDA, se preparan bajo la sección 503A de la Ley Federal de Alimentos, Medicamentos y Cosméticos contra una prescripción para un paciente individual, y son productos de prescripción y no material exclusivamente para uso en investigación. ExaVeyra no suministra sustancias controladas. Esta página se ofrece únicamente con fines informativos. No constituye consejo médico, no está destinada a diagnosticar, tratar, curar ni prevenir ninguna enfermedad, y no sustituye el criterio de un profesional con licencia. Consulte a un profesional de la salud antes de actuar sobre cualquier cosa que aquí se afirme. La FDA no ha aprobado el GHK-Cu ni ningún producto de exosomas para la caída del cabello ni para ninguna forma de alopecia. Los medicamentos compuestos no están aprobados por la FDA; los prepara una farmacia de preparados magistrales 503A con licencia para un paciente individual según la prescripción de ese paciente, y se suministran únicamente a profesionales con licencia verificados por NPI. Cuando esta página trata un principio activo aprobado por la FDA, como la finasterida oral o el minoxidil tópico, rige el etiquetado del producto aprobado y nada de lo aquí expuesto lo modifica. ExaVeyra Sciences es un proveedor y no participa en ningún diagnóstico, decisión de tratamiento ni plan de atención. ExaVeyra Sciences no suministra sustancias controladas. Los hallazgos descritos en esta página se atribuyen a la literatura revisada por pares y a las agencias citadas, y una cita establece que una pregunta fue estudiada, no que un producto sea adecuado para un paciente determinado. El contenido de estas guías se ofrece únicamente con fines informativos generales. No constituye asesoramiento legal, médico ni regulatorio, y no debe interpretarse como una confirmación de que determinado producto o determinada práctica cumple con la normativa aplicable. Los requisitos regulatorios varían según el estado y dependen de las circunstancias de cada práctica. Cada profesional debe consultar a su propio asesor legal y a las juntas estatales de licenciamiento aplicables antes de actuar sobre cualquier cosa que aquí se afirme.

Solo de referencia. No constituye asesoramiento legal ni médico.

El contenido de estas guías se ofrece únicamente con fines informativos generales. No constituye asesoramiento legal, médico ni regulatorio, y no debe interpretarse como una confirmación de que determinado producto o determinada práctica cumple con la normativa aplicable. Los requisitos regulatorios varían según el estado y dependen de las circunstancias de cada práctica. Cada profesional debe consultar a su propio asesor legal y a las juntas estatales de licenciamiento aplicables antes de actuar sobre cualquier cosa que aquí se afirme.

Leer el descargo completo

ExaVeyra Sciences publica estas guías como referencia para profesionales con licencia. Resumen requisitos federales y estatales de acceso público tal como esos requisitos se leían en la fecha de revisión indicada arriba. El contenido se ofrece únicamente con fines informativos generales, no constituye asesoramiento legal, médico ni regulatorio, y no debe interpretarse como una confirmación de que determinado producto o determinada práctica cumple con la normativa aplicable.

El acceso a estos materiales no crea ninguna relación abogado-cliente ni ninguna relación profesional o clínica de ningún tipo. ExaVeyra Sciences es un proveedor de materiales para uso en investigación. No es un despacho de abogados, no es un consultor regulatorio, y no participa en ningún diagnóstico, decisión de tratamiento ni plan de atención. Cada profesional es responsable de contratar a su propio asesor legal y de determinar, junto con ese asesor y las juntas estatales de licenciamiento aplicables, cómo se aplican los requisitos aquí descritos a los servicios, la dotación de personal y la estructura de su propia práctica.

Las leyes, los reglamentos, las normas de las juntas y las posiciones de las agencias están sujetos a modificación, sustitución y reinterpretación. ExaVeyra Sciences no formula declaración ni garantía alguna sobre la exactitud, integridad, vigencia o aplicabilidad de este contenido a ninguna práctica en particular. Las citas y los enlaces a fuentes de terceros se ofrecen únicamente por conveniencia y no constituyen un respaldo de su contenido.

El profesional y la práctica son los únicos responsables del cumplimiento de todos los requisitos aplicables de licenciamiento, ámbito de práctica, supervisión, propiedad, instalaciones, mantenimiento de registros e impuestos, y de todas las decisiones clínicas, incluida la idoneidad de cualquier material para un paciente dado. En la máxima medida permitida por la ley, ExaVeyra Sciences renuncia a toda responsabilidad por cualquier acción tomada o no tomada en función de este contenido.